CBER head Prasad adds chief medical and scientific officer to his title

Zachary Brennan

Senior Editor

Vinay Prasad, the newly-minted chief of the FDA’s biologics center, will now have two additional roles as chief medical and scientific officer, FDA Commissioner Marty …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

CBER head Prasad adds chief medical and scientific officer to his title

Zachary Brennan

Senior Editor

Sign up to read this article for free.

How a tailored ALS drug could help broaden rare disease therapies

Scholar Rock’s muscle-preserving obesity drug add-on looks competitive

FDA unveils one-year pilot to speed some new drugs to market in just one month

Gilead gets groundbreaking FDA approval for twice-yearly HIV prevention shot

After a quiet year, Xaira unwraps some of its AI research, eyeing a virtual cell

This company has spent a decade innovating NGS-based companion diagnostics worldwide–what’s next?

CBER head Prasad adds chief med­ical and sci­en­tif­ic of­fi­cer to his ti­tle

Zachary Brennan

Senior Editor

Sign up to read this article for free.

How a tai­lored ALS drug could help broad­en rare dis­ease ther­a­pies

Schol­ar Rock’s mus­cle-pre­serv­ing obe­si­ty drug add-on looks com­pet­i­tive

FDA un­veils one-year pi­lot to speed some new drugs to mar­ket in just one month

Gilead gets ground­break­ing FDA ap­proval for twice-year­ly HIV pre­ven­tion shot

Af­ter a qui­et year, Xaira un­wraps some of its AI re­search, eye­ing a vir­tu­al cell

This com­pa­ny has spent a decade in­no­vat­ing NGS-based com­pan­ion di­ag­nos­tics world­wide–what’s next?

CBER head Prasad adds chief medical and scientific officer to his title

How a tailored ALS drug could help broaden rare disease therapies

Scholar Rock’s muscle-preserving obesity drug add-on looks competitive

FDA unveils one-year pilot to speed some new drugs to market in just one month

Gilead gets groundbreaking FDA approval for twice-yearly HIV prevention shot

After a quiet year, Xaira unwraps some of its AI research, eyeing a virtual cell

This company has spent a decade innovating NGS-based companion diagnostics worldwide–what’s next?